European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	80
Early initiation of SGLT2 inhibitors after acute myocardial infarction	65
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	61
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	57
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	55
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	45
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	41
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	40
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	39
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead	38
The role of aetiology in determining anticoagulation effectiveness for the treatment of Left Ventricular Thrombus	35
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	32
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	31
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	30
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	30
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	28
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	28
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	27
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	27
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	26
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	24
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	23
All about clinical trials	23

New ways of mitigating aldosterone in cardiorenal disease	23
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	22
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	22
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	21
Late breaking clinical trials at ACC 22	21
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients	21
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	21
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	20
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	20
De-escalation versus shortening of dual antiplatelet therapy	20
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation	20
Cardiovascular prevention and risk factors	20
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al .	19
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	19
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	19
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	17
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	17
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	16
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	16
Entering a new era of antiplatelet therapy: the 4D-ACS trial	16
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	16
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	16
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	16
Are NOACs always the best strategy in elderly AF patients?	15
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	15
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	15
Photoinduced skin reactions of cardiovascular drugs—a systematic review	15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	15
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’	15
Focus on different aspects of atrial fibrillation	14
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	14
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	14
What's new in pharmacotherapy at ESC Congress 2023?	13
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	13
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	13
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	13
Different aspects of pharmacological heart failure treatment	13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	13
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	13
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome	13
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	13
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	13
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	13
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials	13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	13
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	12
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	12
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	12

An old drug in a new era: digitoxin in the spotlight after DIGIT-HF	12
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	11
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	11
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	11
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	11
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	10
RNA-targeted therapeutics in cardiovascular disease: the time is now	10
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials	10
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	10
FLOW trial stopped early due to evidence of renal protection with semaglutide	10
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis	9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	9
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	9
Future of antithrombotic therapy for heart failure with coronary artery disease	8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	8
Special focus on the new anti-diabetic drugs	8
Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study	8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	8
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial	8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	8
Management of dyslipidaemia in patients with comorbidities: facing the challenge	7
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug	7
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT	7
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation	7
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	7
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	7
Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI	7
Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RA	7
Lipid treatment	7
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	7
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	7
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI	7
Correction to: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	7
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	6
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	6
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	6
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	6
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	6
LDL lowering effect of PCSK9 inhibition is reduced in women	6
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	6
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	6
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis	6
The search for the perfect antiplatelet treatment continues	6
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	6
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	6
The role of cangrelor in acute and high-risk PCI settings	6
Early DAPT discontinuation after acute myocardial infarction: finding the optimal TARGET	6
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	6
Pharmacogenetic testing to broaden patient eligibility for mavacamten	6
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	5
End of the first decade of EHJ CVP	5
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	5
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	5
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	5
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	5
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis	5
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	5
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study	5
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	5
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	5
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	5
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	5
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	5
EHJCVP Reviewers 2022	5
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	5
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	5
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	5
Our knowledge about atrial fibrillation steadily increases	5
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	5
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	5
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	5

Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials	4
Reaping the rewards of a simplified dosing regimen	4
Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	4
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants	4
Optimizing individual heart failure treatment	4
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD	4
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	4
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	4
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	4
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	4
Sex-related differences in platelet aggregation	4
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study	4
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure	4
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	4
Reply to ‘Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction’	4
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy	4
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease	4
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational	4
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study	4
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study	4
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension	3
ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy)	3
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	3
VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention	3
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA	3
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	3
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	3
Bleeding and thrombosis	3
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data	3
Subcutaneous furosemide in heart failure: a systematic review	3
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction	3
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock	3
Fibrates: one more lost paradise in lipid treatment	3
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension	3
Oral anticoagulants and antiplatelet treatment in different settings	3
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study	3
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	3
Post-operative atrial fibrillation and stroke after non-cardiac surgery: a systematic review and meta-analysis	3
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials	3
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	3
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	3
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	3
Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis	3
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	3
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	3